RegWardenFDA facility compliance records
Recall

Class II — DePuy Mitek, Inc., a Johnson & Johnson Co.

Recalling firmDEPUY MITEK, A JOHNSON & JOHNSON COMPANY
Registered facilityDePuy Mitek, Inc. (the firm's only registered facility)
ClassificationClass II
StatusOngoing
ReasonIFU Warning: Applying bending force and/or bending force with impaction to the BIOKNOTLESS® Anchor Inserter may cause a fragment of the inserter tip to break off during use and be retained in the patient. broken BIOKNOTLESS® Anchor inserter tip detected during surgery may require removal, potentially causing bone damage and longer surgery time
ProductDePuy Mitek BIOKNOTLESS Rapid w/ Pan-Indicated for use in soft tissue to bone fixation in association with adequate postoperative immobilization Model Number: 212723
Quantity1125 units
DistributionWorldwide distribution - US Nationwide and the countries of Australia, Belgium, Canada, Switzerland, China, Czech Republic, Germany, Egypt, Spain, United Kingdom, Hong Kong, Hungary, Ireland, India, Italy, Korea, Netherlands, New Zealand, Slovakia, Thailand.
Initiated2023-04-13
Classified2023-06-02
Recall numberZ-1681-2023
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — DePuy Mitek, Inc., a Johnson & Johnson Co. (Z-1681-2023).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/92210/

Not open yet

Alerts for DEPUY MITEK, A JOHNSON & JOHNSON COMPANY

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.